Uppdatering om A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLNFGFR1)
Presenterad under ASH-konferensen 21-12-12.
Senast uppdaterad 17 januari 2022